Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MeiraGTx

- PMLiVE

Private equity firm backs Ferring gene therapy venture

Joint venture will focus on development of therapies for bladder cancer

- PMLiVE

Solid Bio falls as FDA halts DMD trial over safety concerns

Shares in the biotech dropped dramatically following the announcement

- PMLiVE

Personalised medicine can improve treatment, but access still an issue

Barriers to access could harm uptake of potentially transformative therapies

- PMLiVE

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

- PMLiVE

J&J proposes $4bn in cash to settle opioid crisis allegations

Upcoming federal trial puts a number of companies in the spotlight

- PMLiVE

Litigation concerns threaten to overshadow solid quarter at J&J

Reports better-than-expected financial results

- PMLiVE

Sarepta bounces back with new gene therapy data

Announces positive results in treatment of limb-girdle muscular dystrophy

- PMLiVE

J&J pledges $500m investment into HIV and tuberculosis R&D

Aims to help eliminate both diseases by 2030

- PMLiVE

J&J bags FDA breakthrough designation for prostate cancer drug

Could challenge rival PARP inhibitor Lynparza

- PMLiVE

J&J’s Invokana gets lifeline with new kidney disease approval

Sales have been down since drug was linked to amputation risk

- PMLiVE

J&J expands Darzalex use with another first-line FDA approval

Could help defend myeloma franchise against rival Sanofi

- PMLiVE

bluebird bio reveals further encouraging data for CALD gene therapy

Study shows continued benefit in treatment of rare disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links